GLAXF News and Press, GlaxoSmithKline Plc From 02/24/21

There is growing demand for AI use in drug development. Drug development deals go from $5 million to over $1 billion. Predictive Oncology has a unique platform using real patient samples in its AI process. Predictive Oncology could be undervalued if it can ink large or multipl...

Protagenic Therapeutics has filed to raise $17.5 million in an IPO, although the final figure may differ. The company is developing a treatment candidate for PTSD, depression and anxiety conditions. PTIX is a tiny firm still at a preclinical stage, so is ultra-high risk. For...

Fisher’s 13F portfolio value increased from $117.8B to $133.5B in Q4 2020. They increased Alphabet and Total SA during the quarter. Fisher has a number of small positions in several ETFs/ETNs. For further details see: Tracking Ken Fisher's Fisher Asset Management ...

GSK's yield has been 5-6% lately, which for a quality pharma is attractive. That, and no rise for many years, suggests it may be not be supported. The company has now said it will likely cut its future payout (after the spinoff), with fuller details expected in June. There is ...

GlaxoSmithKline (GSK) Q4 2020 Earnings Conference Call February 3, 2021 9:00 am ET Company Participants Emma Walmsley - Chief Executive Officer Iain Mackay - Chief Financial Officer Luke Miels - President, Global Pharmaceuticals David Redfern - Chief Strategy Officer Brian McNamara - Chief Ex...

The following slide deck was published by GlaxoSmithKline plc in conjunction with their 2020 Q4 earnings call. For further details see: GlaxoSmithKline plc 2020 Q4 - Results - Earnings Call Presentation

Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers. BOLT has produced early efficacy results for its lead program and has an impressive investor syndicate, so the IPO is worth consideration...

We see positive long-term outlook for the company benefiting from strong product portfolio and pipeline as well as its market leading position. GSK is cheap relative to its competitors and value should be unlocked from multiples expansion. We like the 5.5% dividend yield and divid...

Since 2009, Glassdoor has released a yearly ranking of the "Best Places To Work" based on data collected from employees. Glassdoor recently revealed their 2021 ranking. In the past 12 years, Glassdoor's Best Places To Work have more than doubled the returns of the S&P 500 with...

Veeva is building the Industry Cloud for the global life sciences industry with solutions including a CRM suite, content and data management, and AI-powered data analytics. In Q3, Veeva reported a revenue growth rate of 34% y/y (acceleration) and a healthy gross margin of 72% (q/q imp...